Pinealon — Deep Research (Cognitive & Nootropic)

Published · Researched 2026-09-21

Research file written 2026-09-21. Social-first methodology: community sources weighted before vendor pages.

1. Overview

Pinealon is a tripeptide bioregulator from the St. Petersburg Khavinson peptide program — the same research lineage as Epithalon. Identity: Glu-Asp-Arg (EDR), formula C₁₅H₂₆N₆O₈, molecular weight 418.4 g/mol, PubChem CID 18220191, also called the "T-33 peptide" (Eon Peptides / Licensed Peptides spec tables, 2026; Reign Peptide molecular profile). It is one of the shortest compounds in this category — three amino acids — and its proposed mechanism is unusual: rather than binding a receptor, short bioregulator peptides are studied for direct interaction with DNA / gene-expression modulation and neuroprotection in neuronal oxidative-stress and low-oxygen models (Eon Peptides research monograph).

Western replication of the bioregulator mechanism remains limited; a 2026 evidence review found no Pinealon-specific human pharmacokinetic evidence proving absorption, half-life, tissue distribution, or brain exposure. Human benefit, long-term safety, and therapeutic window remain unestablished.

2. Social standing

A small but real anecdote lane, per the June-2026 GitHub hukus/llimitless scan: sleep/recovery/TBI/alertness anecdotes exist but the compound is de-ranked vs. the major nodes.

• Community reports: anecdotal signal centers on mood, sleep, concentration, clarity, speed of thought, and vivid dreams. One reported 30-day experience described improved mood, sleep, and concentration without mental fatigue. A Longecity quote described clarity/speed of thought and memory effects (LimitlessMindset Pinealon page; Longecity quotes).
• YouTube: self-experiment and explainer videos exist (two linked creator videos) — individual accounts, not evidence.
• Looksmax "peptide gigathread": lists Pinealon among frontier bioregulators — name recognition only.
• Recurring praise: the sleep/mood/clarity cluster; "no mental fatigue" framing.
• Recurring complaints / failure modes: essentially none documented — the footprint is too thin for failure modes to emerge, which is itself a data point about low adoption.
• Overhyped warnings: vendor copy that presents gene-expression regulation and neuroprotection as established human effects is UNVERIFIED — no human pharmacokinetic or efficacy data was found; the 2026 evidence review explicitly notes the absence of human PK evidence.

3. Social validation — Tier 3 (single-platform/weak signal, explicitly flagged)

• LimitlessMindset Pinealon page + Longecity quotes: prove a small anecdote lane exists (mood, sleep, concentration, clarity, vivid dreams; one 30-day experience). Proves real-world discussion, minimal density.
• YouTube creator videos (two): prove individual self-experimentation is documented on video. Proves minimal real-world use.
• June-2026 GitHub hukus/llimitless scan: proves Pinealon has a visible but de-ranked anecdote lane (sleep/recovery/TBI/alertness). Proves it registers in community datasets, far below the major nodes.
• Vendor spec tables (Eon, Reign, Licensed, Real Peptides): prove consistent identity (EDR tripeptide, 418.4 g/mol) across multiple US vendors with COA claims — the identity story is unusually consistent for this market.
• Missing: no named Facebook Group posts, no Threads owner content, no Instagram owner content surfaced this round; no human trials of any kind.

4. Key specs table

5. Pricing (observed 2026-09-21)

Marketplace used range: not observed — report honestly, no used-market data found. Street range clusters $40–70 per 10 mg vial — mid-pack for this category, cheap per milligram given the tiny 418 Da molecule (a 10 mg vial is ~24 µmol, more molecules per dollar than any other item in this track).

6. What's included / what's needed

• Lyophilized vial ships as powder; reconstitution solution typically sold separately.
• No reconstitution or dosing protocol exists in any research literature; all use protocols are community folklore.

7. Support reality

• COA culture: Eon advertises ISO/IEC 17025-accredited US lab testing with QR-authenticated batch traceability; Reign and Real Peptides claim ≥99% third-party HPLC with published COAs. This is the better end of the bioregulator market.
• Identity consistency: unusually consistent across vendors (EDR, 418.4 g/mol, T-33) — a genuine positive vs. the Adamax identity chaos.
• Gray-market risk: research-use-only labeling in the US; the bioregulator framing sometimes sits in supplement-adjacent marketing, which muddies the QA picture.

8. Community verdict

Pinealon is the category's quiet bioregulator: consistent identity, mid-range pricing, a small sincere anecdote lane (sleep, mood, clarity), and no human data whatsoever. Nobody hates it because almost nobody has tried it at scale; nobody can vouch for it for the same reason. The honest position: interesting short-peptide mechanism on paper, UNVALIDATED in humans, priced fairly for a frontier SKU.

9. Regulatory & safety status

• USA/EU: not FDA or EMA approved; sold as a research chemical not for human use (US). No human pharmacokinetic, efficacy, or long-term safety data found.
• Russia/CIS: bioregulator peptides of the Khavinson lineage have medical use history in Russia, but no Pinealon-specific registration documentation was found this round — do not assume registered status.
• Community-reported side effects: none documented in this session's extraction (footprint too thin for a safety signal in either direction).

Images

4/8 views present in img/: pinealon-hero.jpg, pinealon-top.jpg, pinealon-detail.jpg, pinealon-box.jpg. All verified valid JPEGs. Missing views: side, rear, scale, in-use/owner photo — no distinct real photos found for these views; named honestly.

Not medical advice. This is community research, not a recommendation. Pinealon is an unapproved research chemical with no human safety data; it is not for human use. Talk to a clinician before considering any peptide.

Named sources

• Eon Peptides — Sequence: Glu-Asp-Arg (EDR) — tripeptide (2026)
• Reign Peptide — Sequence: Glu-Asp-Arg (EDR) — tripeptide (2026)
• Licensed Peptides — Synonyms: T-33 peptide; Glutamylaspartylarginine
• Vendor research pages — Class: Short-peptide bioregulator (Khavinson lineage)
• Eon monograph — Proposed mechanism: DNA/gene-expression interaction; neuroprotection in oxidative-stress models — Western replication limited
• YouTube — self-experiment and explainer videos exist (two linked creator videos) — individual accounts, not evidence.
• Looksmax "peptide gigathread" — lists Pinealon among frontier bioregulators — name recognition only.
• YouTube creator videos (two) — prove individual self-experimentation is documented on video.

Source URLs were not recorded for these references.